V943A
Biological
Merck Sharp & Dohme Corporation
Total Payments
$250,731
Transactions
12
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $107,448 | 6 | 0 |
| 2019 | $143,283 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $250,731 | 12 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Open-Label, Phase 2 Trial of CMB305 Sequentially Administered LV305 and G305 and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1 | Merck Sharp & Dohme Corporation | $175,982 | 0 |
| Phase 1 Study of Cellular Adoptive Immunotherapy using autologous CD8NY-ESO-1-Specific T cells and the NY-ESO-1 Immunostimulatory agents L V305 or CMB305 for Patients with sarcoma | Merck Sharp & Dohme Corporation | $62,500 | 0 |
| A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 Sequentially Administered LV305 and G305 in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Merck Sharp & Dohme Corporation | $12,249 | 0 |
Top Doctors Receiving Payments for V943A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Palo Alto, CA | $250,731 | 12 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $250,731
Product Information
- Type Biological
- Total Payments $250,731
- Total Doctors 0
- Transactions 12
About V943A
V943A is a biological associated with $250,731 in payments to 0 healthcare providers, recorded across 12 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $107,448 was paid across 6 transactions to 0 doctors.
The most common payment nature for V943A is "Unspecified" ($250,731, 100.0% of total).
V943A is associated with 3 research studies, including "A Randomized, Open-Label, Phase 2 Trial of CMB305 Sequentially Administered LV305 and G305 and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1" ($175,982).